This preprint is under consideration at Journal of Nanobiotechnology. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Jiulong Zhao
Changhai Hospital Department of Gastroenterology
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
The combination of photothermal therapy (PTT) and photodynamic therapy (PDT) has attracted attention due to its enhanced tumor synergetic effect. This study proposes a novel nanoenzyme-based theranostic nanoplatform, IrO2@[email protected](Ce6), for the combined PTT and PDT of tumors. IrO2 was prepared by a simple hydrolysis method and coated with a thin layer of mesoporous silica (MSN) to facilitate the physical adsorption of Chlorin e6 (Ce6). The PDA coating and IrO2 NPs of the nanoplatform demonstrated an improved photothermal conversion efficiency of 29.8 % under NIR irradiation. Further, the Ce6 loading imparts materials with the ability to produce reactive oxygen species (ROS) under 660 nm NIR laser irradiation. It was also proved that the IrO2 NPs could catalyze the hydrogen peroxide (H2O2) in the tumor microenvironment (TME) to generate endogenous oxygen (O2), thereby enhancing the efficiency of PDT. The in vitro and in vivo experiments indicated that the nanocomposites were highly biocompatible and could produce a satisfactory tumor therapeutic effect. Thus, the findings of the present study demonstrate the viability of using theranostic nanoenzymes for translational medicine.
Keywords
Photothermal therapy, Photodynamic therapy, Cancer treatment, Biocompatibility, Iridium nanocomposite
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
This is a list of supplementary files associated with this preprint. Click to download.
- Scheme01.png
Scheme 1. The schematic synthesis procedure and therapeutic mechanism of [email protected]@PDA-BSA(Ce6)
- Supportinformation.docx
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
Version 1
Posted 06 Apr, 2021
No community comments so far
Editorial decision: Major revision
On 21 Apr, 2021
Review #4 received
Received 20 Apr, 2021
Review #3 received
Received 14 Apr, 2021
Review #2 received
Received 14 Apr, 2021
Review #1 received
Received 09 Apr, 2021
Reviewer #4 agreed
On 05 Apr, 2021
Reviews received
Received 02 Apr, 2021
Reviewer #2 agreed
On 01 Apr, 2021
Reviewer #3 agreed
On 01 Apr, 2021
Reviewers invited
Invitations sent on 01 Apr, 2021
Reviewer #1 agreed
On 01 Apr, 2021
Editor assigned
On 31 Mar, 2021
Submission checks complete
On 31 Mar, 2021
Editor invited
On 31 Mar, 2021
First submitted
On 29 Mar, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Nanoscience
Learn more about our company.
This preprint is under consideration at Journal of Nanobiotechnology. A preprint is a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research
Jiulong Zhao
Changhai Hospital Department of Gastroenterology
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Under Revision
Version 1
Posted 06 Apr, 2021
No community comments so far
Editorial decision: Major revision
On 21 Apr, 2021
Review #4 received
Received 20 Apr, 2021
Review #3 received
Received 14 Apr, 2021
Review #2 received
Received 14 Apr, 2021
Review #1 received
Received 09 Apr, 2021
Reviewer #4 agreed
On 05 Apr, 2021
Reviews received
Received 02 Apr, 2021
Reviewer #2 agreed
On 01 Apr, 2021
Reviewer #3 agreed
On 01 Apr, 2021
Reviewers invited
Invitations sent on 01 Apr, 2021
Reviewer #1 agreed
On 01 Apr, 2021
Editor assigned
On 31 Mar, 2021
Submission checks complete
On 31 Mar, 2021
Editor invited
On 31 Mar, 2021
First submitted
On 29 Mar, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Nanoscience
License:
This work is licensed under a CC BY 4.0 License. Read Full License
The combination of photothermal therapy (PTT) and photodynamic therapy (PDT) has attracted attention due to its enhanced tumor synergetic effect. This study proposes a novel nanoenzyme-based theranostic nanoplatform, IrO2@[email protected](Ce6), for the combined PTT and PDT of tumors. IrO2 was prepared by a simple hydrolysis method and coated with a thin layer of mesoporous silica (MSN) to facilitate the physical adsorption of Chlorin e6 (Ce6). The PDA coating and IrO2 NPs of the nanoplatform demonstrated an improved photothermal conversion efficiency of 29.8 % under NIR irradiation. Further, the Ce6 loading imparts materials with the ability to produce reactive oxygen species (ROS) under 660 nm NIR laser irradiation. It was also proved that the IrO2 NPs could catalyze the hydrogen peroxide (H2O2) in the tumor microenvironment (TME) to generate endogenous oxygen (O2), thereby enhancing the efficiency of PDT. The in vitro and in vivo experiments indicated that the nanocomposites were highly biocompatible and could produce a satisfactory tumor therapeutic effect. Thus, the findings of the present study demonstrate the viability of using theranostic nanoenzymes for translational medicine.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Loading...